Article ID,Publication Year,Reference,US$/QALY *,Ratio Description,PubMed ID,Target Population,Intervention Description,Title,Comparator Description,Impact
2012-01-09611,2012,Casciano 2012 J Med Econ,40000,Everolimus (10mg daily) VERSUS Sunitinib (37.5mg daily) IN Patients with advanced progressive pancreatic neuroendocrine tumors,22881362,Patients with advanced progressive pancreatic neuroendocrine tumors,Everolimus (10mg daily),"Cost-effectiveness of everolimus vs sunitinib in treating patients with advanced, progressive pancreatic neuroendocrine tumors in the United States.",Sunitinib (37.5mg daily),NE
1,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
